David1949 wrote:
"
I think, compared to traveling to a foreign country to have one's veins roto-routed, it would seem to me to be fairly low on the reckless scale. "Well I guess if liberation is like having one's veins roto-routed then Daflon is akin to pouring Draino into the veins.
I am somewhat concerned by Blossom's post which indicates that Tysabri works in somewhat the same manner as Daflon, by keeping the leukocytes from sticking to the vein walls. We all know what Tysabri can do.

Except Daflon isn't a toxic substance and therefore is unlike drinking Draino (and safer than eating dogie doodoo). You would have to ingest 360 pills at once to reach a lethal dose. A lethal dose of Draino I expect can be achieved at far lower amounts.
Daflon 500mg vs. Tysabri is an interesting proposition though.
The mode of action of Tysabri is described as:
Quote:
Natalizumab is a humanized monoclonal antibody against alpha-4 (α4) integrin, the first drug developed in the class of selective adhesion molecule inhibitors. α4-integrin is required for white blood cells to move into organs; natalizumab's mechanism of action is believed to be the inhibition these immune cells from crossing blood vessel walls to reach affected organs.
This is to be contrasted with Daflon 500mg's described mode of action on microcirculation:
Quote:
At the microcirculation level, DAFLON 500 mg reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from damaging processes. DAFLON 500 mg reduces the expression of endothelial adhesion molecules (ICAM1, VCAM1), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and prostaglandins (PGE2, PGF2).
This protective and reinforcing action on the venous and lymphatic system, associated with the vasculoprotective effect on the microcirculation, explains the restorative and protective efficacy of DAFLON 500 mg in chronic venous insufficiency and haemorrhoidal disease, both of which are associated with perivascular inflammation and edema.
There is no reported risk of PML with Daflon and it isn't considered immune-suppressive, nor is it a cloned antibody. Query whether it holds the same promise as Tysabri, but witout the risk of PML? And doubly so in combination with liberation? Indeed a consequence of CCSVI research may be to shift the focus of pharmacological intervention in MS from autoimmune suppression to microcirculation and after that who knows what beneficial treatments are out there waiting to be discovered.
Perhaps, Daflon 500mg?